



CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

MINUTES OF THE PRE-BIDDING CONFERENCE
04 MARCH 2021 | 10:00 A.M. | COBAC CONFERENCE ROOM

PROCUREMENT OF VARIOUS TESTING REAGENTS AND LABORATORY SUPPLIES

I. ATTENDEES

A. CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) - C:

- | | |
|--------------------------------|----------------------------|
| 1. Dir. Angelina A. Del Mundo | - Vice-Chairperson |
| 2. Engr. David P. Masiado, Jr. | - Regular Member |
| 3. Dr. Anthony B. Cu | - Alternate Regular Member |

ABSENT:

- | | |
|--------------------------|-----------------|
| 1. Asec. Romeo A. Ong | - Chairperson |
| 2. Dir. Gloria J. Balboa | -Regular Member |
| 3. Dir. Faith F. Alberto | -Regular Member |

B. COBAC-C SECRETARIAT

1. Ms. Genicar N. Barotilla
2. Ms. Maria Charisma Lorenzo
3. Ms. Farra Pae Maglalang
4. Mr. Govanne Marie Agudo
5. Ms. Celine Velasco
6. Ms. Ianna Miralles
7. Ms. Frances Jamaika Soliven
8. Mr. Jan Carlo Palugod

C. END-USER REPRESENTATIVES/TECHNICAL WORKING GROUP MEMBERS:

- | | |
|-----------------------------|----------------------------|
| 1. Dr. Stephen Dave Chua | - PBC (attended via webex) |
| 2. Mr. Michael Angelo Goita | - PBC (attended via webex) |

D. PROSPECTIVE BIDDERS (PBs):

- | | |
|----------------------------|---|
| 1. Ms. Maria Airene Daag | -Scientific Biotech Specialties Inc. |
| 2. Mr. Alvin Gragas | -Allied Hospital Supply International Corporation |
| 3. Ms. Heidi Fababier | -Abbott Laboratories (via webex) |
| 4. Ms. Irene Cunanan | -Abbott Laboratories (via webex) |
| 5. Ms. Luz Lorenzo | -Great Breed Enterprises Company (via webex) |
| 6. Mr. Aaron Santos | -Ortho Clinical Diagnostic (via webex) |
| 7. Mr. Jerald R. Quines | -Marsman Drysdale Medical Products (via webex) |
| 8. Ms. Michelle Villanueva | - Marsman Drysdale Medical Products (via webex) |

II. AGENDA

Reference No.	Project Name	ABC (PhP)
IB No. 2021-146	Procurement of Reagents for Screening Antibodies to Human Leukocytes Antigen (HLA) and Human Neutrophil Antigens (HNA) with Machine Tie-up	14,800,000.00
IB No. 2021-147	Procurement of SARS-COV2 IgG Reagent for Fully Automated Testing with Machine Tie-up and SARS-COV2 IgM or Total Antibody Reagent for Fully Automated Testing with Machine Tie-up	4,500,000.00
IB No. 2021-148	Procurement of Various Testing Reagents and Laboratory Supplies for Blood and Blood Products	10,985,700.00

III. CALL TO ORDER

The Pre-Bidding Conference for the above-cited procurement projects were conducted on 04 March 2021 at 10:00 AM at the COBAC Conference Room, Bldg. 6, Department of Health. It was called to order and presided over by Dir. Angelina Del Mundo, COBAC-C Vice-Chairperson.

IV. MINUTES

- 1) The Vice-Chairperson led the opening remarks. She introduced the COBAC-C members and the End-user representatives, then acknowledged the presence of the prospective bidders' representatives who joined the conference through Webex. However, there were no attendees for the following procurement projects:
 - Procurement of Reagents for Screening Antibodies to Human Leukocytes Antigen (HLA) and Human Neutrophil Antigens (HNA) with Machine Tie-up
 - Procurement of Various Testing Reagents and Laboratory Supplies for Blood and Blood Products
- 2) The COBAC-C asked the PBs if they have previously joined other government biddings to confirm if they are already familiar with the documentary requirements.
- 3) The COBAC-C informed the PBs that they will first discuss the common requirements for the cited procurement projects and eventually go through the discussion of the Approved Budget for the Contract, Schedule of Requirements and Technical Specification.
- 4) The following subject matters were emphasized:
 - a. Section III. Bid Data Sheet including:
 - Eligibility Requirements
 - Technical Documents
 - Financial Requirements
 - Post-Qualification Requirements
 - b. Special Conditions of Contract (SCC) under Section V of Bidding Documents
 - c. Schedule of Requirements under Section VI of Bidding Documents
 - d. Technical Specifications under Section VII of Bidding Documents
 - e. Bidding Forms under Section VIII of Bidding Documents

5) The following were the issues and concerns raised by the prospective bidders:

a. Schedule of Requirements:

Particulars	Issues/Concern	Discussion/Decision
Delivery Schedule	<ul style="list-style-type: none"> The PB asked if the project is one time delivery. 	<ul style="list-style-type: none"> The end user representative confirmed that the delivery schedule is one time delivery – thirty (30) calendar days from receipt of Notice to Proceed

b. Technical Specification – the issues and concerns raise were applicable for both Item Nos. 1 and 2.

Particulars	Issues/Concern	Discussion/Decision
2. Chemiluminescence Immuno assay (CLIA) or Enhanced Chemiluminescence Immuno assay (eCLIA)	<ul style="list-style-type: none"> The PB asked if enzyme-linked immunosorbent assay (ELISA) can be accepted. 	<ul style="list-style-type: none"> The end user representative noted the query and will discuss on the matter
3. With a result of at least 95% or higher for Specificity and 95% or higher for Sensitivity	<ul style="list-style-type: none"> The PB asked if the Specificity and Sensitivity result can lower to at least 89%. 	
4. Provision of reagent specific controls in the manufacturer's kit:	<ul style="list-style-type: none"> The PB asked if the packaging for controls are outside or separate box of the kit. 	<ul style="list-style-type: none"> The end user representative accepted the said packaging as long as the controls must be provided and included in the kit.
5. Provision of one (1) machine and back up unit that is fully automated and utilizing the same reagents to be returned upon consumption of reagents	<ul style="list-style-type: none"> The PB asked if they still need to provide another machine if they already provided the existing machine in the institution. 	<ul style="list-style-type: none"> The end user representative said that the supplier still need to provide a machine because it will be used in another unit/section. Also, the COBAC-C said that the bidder must provide since it is different bidding and included in the requirement.
Shelf life: a) Must be fresh commercial stock with a total shelf life of six (6) months from the date of manufacture but not less than 3 months from the date of delivery	<ul style="list-style-type: none"> The PB asked if required shelf life can be lowered to three to four months with guarantee letter. 	<ul style="list-style-type: none"> The EU responded that it must be six months. The COBAC-C told the end user to clarify the required shelf life since based on the statement it is acceptable.

c. Additional Requirement – issues and concerns raised were applicable for both item nos. 1 and 2

Particulars	Issues/Concern	Discussion/Decision
1. Valid and current Certificate Product Registration (CPR) or Certificate of Medical Device Registration (CMDR) or Certificate of Exemption or Certificate of Medical Device Notification (CMDN) issued by Philippine Food and Drug Administration (PFDA)	<ul style="list-style-type: none"> The PB asked if Special Certification from PFDA is acceptable since there is still no CPR being issued by PFDA. 	<ul style="list-style-type: none"> The end user representative noted the said query and subject for their review.

5. Guarantee letter from the supplier to replace item with approved shorter shelf life when returned three (3) months before expiry date;	<ul style="list-style-type: none"> • The PB also asked the validity of the guarantee letter, if they still need to replace if the items have been delivered more than a year. • Another PB asked if it possible to only require the guarantee letter if the items to be delivered is less than six months. 	<ul style="list-style-type: none"> • The COBAC-C responded that it will not reach a year since the shelf life was only six months. also, they asked the PB if how many times the supplier will replace the stocks. • The COBAC-C also told the EU to review the said requirement and specify/clarify the conditions applies or required on the project.
---	--	---

- 6) Further, the COBAC-C emphasized that the statement of compliance in the Technical Specifications must be supported by evidence in a Bidders Bid and cross-referenced to that evidence. Moreover, the Committee explained that “the evidence shall be in the form of manufacturer’s un-amended sales literature, unconditional statements of specification and compliance issued by the manufacturer, samples, independent test data, brochure, product insert and others. A statement that is not supported by evidence or is subsequently found to be contradicted by the evidence presented will render the Bid under evaluation liable for rejection”.
- 7) The Committee also emphasized that the project is a lot bidding. The bidder must bid for all items included in the lot and must not exceed the ABC per item.
- 8) The COBAC-C said that the PBs can request for clarifications on any part of the bidding documents or for interpretation must be in writing and submitted to the Committee at least ten (10) calendar days before the deadline set for the submission of bids pursuant to Section 22.5.1 of 2016 Revised IRR of RA 9184.
- 9) In addition, the Committee informed the PBs that all the queries and suggestions raised during the discussion are noted and a Bid Bulletin shall be issued for the changes in the posted Bidding Documents upon confirmation by the End-user.

V. ADJOURNMENT

Having no other matters to be discussed, the meeting was adjourned at 12:30 PM.

Prepared by:

(sgd.)
FARRA PAE. R MAGLALANG
 COBAC-C Secretariat
 04 March 2021

Approved by:

(sgd.)
ANGELINA A. DEL MUNDO, MA, CESO III
 Director IV
 COBAC-C Vice Chairperson